PT - JOURNAL ARTICLE AU - Ferguson, Scott AU - Yang, Katherine S. AU - Zelga, Piotr AU - Liss, Andrew S. AU - Carlson, Jonathan AU - del Castillo, Carlos Fernandez AU - Weissleder, Ralph TI - Single EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer AID - 10.1101/2021.09.26.21263660 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.26.21263660 4099 - http://medrxiv.org/content/early/2021/09/27/2021.09.26.21263660.short 4100 - http://medrxiv.org/content/early/2021/09/27/2021.09.26.21263660.full AB - Tumor cell derived extracellular vesicles (EV) are being explored as circulating biomarkers for cancer detection. Up to now however, clinical results have been mixed for a number of reasons including the predominant use of bulk measurements, the inability to differentiate tumor from host cell derived vesicles, the general absence of uniquely identifying biomarkers and the unknown frequency of stochastically distributed biomarkers into single circulating vesicles. We hypothesized that a single EV analysis (sEVA) technique could potentially improve diagnostic accuracy necessary to detect early cancers but the actual biomarker frequency and practical detection limits are currently unknown. Using pancreatic cancer, we carefully analyzed the composition of putative cancer markers in 11 established and new patient derived models. In parental PDAC cells positive for KRASmut and/or P53mut proteins only ∼40% of EVs were also positive (range: 30-64%). This rate of positivity increased to 57% when additional PDAC biomarkers were considered (MUC1, EGFR, ⍺FG-P4OH) in cell lines. In a blinded study involving 16 patients with surgically proven stage 1 PDAC, KRASmut and P53mut protein was detectable at much lower levels, generally in < 0.1% of vesicles. With the analytical capabilities of sEVA however, 15 of the 16 patients with stage 1 PDAC expressed low levels of biomarker positive EV. Using a modeling approach, we estimate that the current PDAC detection limit is at ∼0.1 cm3 tumor volume, below clinical imaging capabilities. These findings establish the potential for single-EV analysis for early cancer detection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNIH grants: R01CA237332 (NCI), R01CA204019 (NCI), R21CA236561 (NCI), P01CA069246 (NCI).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study was granted by the Massachusetts General Hospital Institutional Review Board (MGH-IRB) and all subjects signed informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available upon request.